Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prodrug activation by enzyme, a promising strategy for chemotherapy

Full text
Author(s):
Lorena Blau [1] ; Renato Farina Menegon [2] ; Man Chin Chung [3]
Total Authors: 3
Affiliation:
[1] Universidade Estadual Paulista 'Júlio de Mesquita Filho'. Faculdade de Ciências Farmacêuticas. Departamento de Fármacos e Medicamentos - Brasil
[2] Universidade Estadual Paulista 'Júlio de Mesquita Filho'. Faculdade de Ciências Farmacêuticas. Departamento de Fármacos e Medicamentos - Brasil
[3] Universidade Estadual Paulista 'Júlio de Mesquita Filho'. Faculdade de Ciências Farmacêuticas. Departamento de Fármacos e Medicamentos - Brasil
Total Affiliations: 3
Document type: Journal article
Source: Química Nova; v. 29, n. 6, p. 1307-1317, 2006-12-00.
Abstract

Strategies that promote selective activation of prodrugs by enzymes can be divided into two major classes: 1) deliver of a monoclonal antibody-enzyme immunoconjugate that can recognize a specific antigen and promote the prodrug to a citotoxic drug, with a high selectivity for the target cells, and 2) selective gene delivery encoding an enzyme that can promote the prodrug to a citotoxic drug for the target cells. In this article are discussed ADEPT (antibody-directed enzyme prodrug therapy), GDEPT (gene-directed enzyme prodrug therapy), VDEPT (virus-directed enzyme prodrug therapy), GPAT (genetic prodrug activation therapy) and PDEPT (polymer-directed enzyme prodrug therapy) approaches, their clinical trials, advantages, disadvantages and perspectives. (AU)

FAPESP's process: 01/01192-3 - Potential antitripanosomal derived from nitro-heterocyclic compounds
Grantee:Elizabeth Igne Ferreira
Support Opportunities: Research Projects - Thematic Grants